Do big R&D budgets justify US premium drug prices? No way, analysts scoff
Do you want a new formula for calculating “excess” prices paid for branded drug prices? A group of healthcare researchers found a ripe prospect: Tackling the premium built into US drug costs.
Big Pharma R&D is a game of blockbusters. Finding one, getting one approved and then building the market is a multibillion-dollar quest. And there’s been considerable focus on the US premium, the extra that big biopharma collects in this country while selling the same drugs in tightly controlled single-payer markets in Europe for much, much less.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.